

# Provider News

## Simply Healthcare Plans, Inc. (Simply)

Provider Services: Medicaid & Florida Healthy Kids: **844-405-4296** • Medicare: **844-405-4297** | <https://provider.simplyhealthcareplans.com>

## Clear Health Alliance (CHA)

Provider Services: Medicaid: **844-405-4296** | <https://provider.clearhealthalliance.com>

## Table of Contents

COVID-19 information — Simply | Medicaid, Florida Healthy Kids, and Medicare Advantage • CHA | Medicaid.....Page 2

### Administrative

Provider notice for COVID-19 testing — Simply | Medicaid, Florida Healthy Kids, and Medicare Advantage • CHA | Medicaid.....Page 3

Important notice: dermatology services vendor transition to Dermatology Network Solutions —

Simply | Medicaid, Florida Healthy Kids, and Medicare Advantage • CHA | Medicaid.....Page 4

Important notice: podiatry services provided by Podiatry Network Solutions —

Simply | Medicaid, Florida Healthy Kids, and Medicare Advantage • CHA | Medicaid.....Page 4

### Policy Updates

New specialty pharmacy medical step therapy requirements — Simply | Medicare Advantage.....Page 5

Medical drug benefit *Clinical Criteria* updates — Simply | Medicare Advantage.....Page 5

#### Prior Authorization:

Prior authorization update for select durable medical equipment items —

Simply | Medicaid and Florida Healthy Kids • CHA | Medicaid.....Page 6

Simply Healthcare Plans, Inc. expands specialty pharmacy precertification list — Simply | Medicare Advantage.....Page 7

Prior authorization updates for medications billed under the medical benefit — Simply | Medicaid and Florida Healthy Kids .....Page 7

#### Medical Policies and Clinical Guidelines:

August 2021 update — Simply | Medicaid • CHA | Medicaid.....Page 8

February 2022 update — Simply | Medicare Advantage .....Page 9

### Products and Programs

Healthy Rewards Healthy Behaviors Program information — Simply | Medicaid and Florida Healthy Kids • CHA | Medicaid.....Page 10



**Want to receive our *Provider News* and other communications via email?**

Submit your email address to **Simply** and **CHA**.

**Simply:**



**CHA:**





Simply Healthcare Plans, Inc. | Medicaid, Florida Healthy Kids, and Medicare Advantage  
Clear Health Alliance | Medicaid

## COVID-19 information

Simply Healthcare Plans, Inc. (Simply) and Clear Health Alliance (CHA) are closely monitoring COVID-19 developments and how the novel coronavirus will impact our customers and provider partners. Our clinical teams are actively monitoring external queries and reports from the Centers for Disease Control and Prevention (CDC) to help us determine what action is necessary on our part.

For additional information, reference the *COVID-19 Updates* page on the [Simply website](#) and [CHA website](#).

SFLPEC-1898-20/SFLCARE-0208-20

# Administrative

Simply Healthcare Plans, Inc. | Medicaid, Florida Healthy Kids, and Medicare Advantage  
Clear Health Alliance | Medicaid

## Provider notice for COVID-19 testing

### Evaluation and management services for COVID testing — professional

Effective with dates of service on or after September 1, 2022, Simply Healthcare Plans, Inc. (Simply) and Clear Health Alliance (CHA) will facilitate review of selected claims for COVID-19 visits reported with evaluation and management (E&M) services submitted by professional providers to align with CMS reporting guidelines. When the purpose of the visit is for COVID-19 testing only, reimbursement for CPT® code 99211 (office or other outpatient visit) is allowed when billed with place of service office (11), mobile unit (15), walk-in retail health clinic (17), or urgent care facility (20). Claims for exposure only may be affected. Professional providers are encouraged to code their claims to the highest level of specificity in accordance with ICD-10 coding guidelines.

Prior to payment, Simply and CHA will review the selected claims to determine, in accordance with correct coding requirements and/or reimbursement policy as applicable, whether the E&M code level submitted is appropriate for the COVID-19 visit reported. If the visit is determined to be solely for the purpose of COVID-19 testing, Simply and CHA will reimburse using CPT code 99211.

Professional providers that believe their medical record documentation supports reimbursement for the originally submitted level for the E&M service will be able to follow the Claims Payment Dispute process (including submission of such documentation with the dispute) as outlined in the provider manual.

SFL-NL-0436-22





## Important notice: dermatology services vendor transition to Dermatology Network Solutions

Effective April 30, 2022, Health Network One will no longer be providing dermatology services for Simply Healthcare Plans, Inc. (Simply) and Clear Health Alliance (CHA) members. Beginning May 1, 2022, Dermatology Network Solutions\* (DNS) will be the statewide subcontractor providing dermatology services to Simply and CHA members.

Providers who are out of network as of May 1, 2022, will be eligible for a 60-day continuity of care period where claims will be payable to allow time for members to transition to a new provider, if necessary. The continuity of care period ends on June 30, 2022. All impacted members were notified by mail on March 1, 2022.

If you are a dermatologist and have questions regarding future network or contract related inquiries, call DNS at **844-222-3535**, Monday to Friday, 8 a.m. to 5 p.m. ET.

For general inquiries related to this transition, call DNS at **844-222-3535**.

*\* Dermatology Network Solutions is an independent company providing dermatology services on behalf of Simply Healthcare Plans, Inc. and Clear Health Alliance.*

SFLPEC-3046-22

## Important notice: podiatry services provided by Podiatry Network Solutions

Effective May 1, 2022, Podiatry Network Solutions\* (PNS) will be the statewide subcontractor providing podiatry services to Simply Healthcare Plans, Inc. (Simply) and Clear Health Alliance (CHA) members. Prior to May 1, 2022, Simply and CHA contracted with podiatry providers directly.

Providers who are out of network as of May 1, 2022, will be eligible for a 60-day continuity of care period where claims will be payable to allow time for members to transition to a new provider, if necessary. The continuity of care period ends June 30, 2022. All impacted members were notified by mail on March 2, 2022.

If you are a podiatrist and have questions regarding future network, contract related inquiries, or for general inquiries related to this communication, call PNS Provider Services at **844-222-3939**, Monday to Friday, 8 a.m. to 5 p.m.

*\* Podiatry Network Solutions is an independent company providing podiatry care services on behalf of Simply Healthcare Plans, Inc. and Clear Health Alliance.*

SFLPEC-3047-22

# Policy Updates



Simply Healthcare Plans, Inc. | Medicare Advantage

## New specialty pharmacy medical step therapy requirements

Step therapy review will apply upon precertification initiation, in addition to the current medical necessity review (as is current procedure). Step therapy will not apply for members who are actively receiving medications listed below.

*Clinical UM Guidelines* are publicly available on the provider website. Visit the [Clinical Criteria page](#) to search for specific criteria.

Effective July 1, 2022, the following Part B medications from the current *Clinical Utilization Management (UM) Guidelines* will be included in our medical step therapy precertification review process.

<i>Clinical UM Guidelines</i>	Preferred drug(s)	Nonpreferred drug(s)
ING-CC-0107	Avastin, Mvasi	Zirabev

SFLCARE-0540-22

Simply Healthcare Plans, Inc. | Medicare Advantage

## Medical drug benefit *Clinical Criteria* updates

On November 19, 2021, January 4, 2022, and February 25, 2022, the Pharmacy and Therapeutics (P&T) Committee approved several *Clinical Criteria* applicable to the medical drug benefit for Simply Healthcare Plans, Inc. These policies were developed, revised, or reviewed to support clinical coding edits.



**Read more online.**

SHPCRNL-0148-22

Visit the [Clinical Criteria website](#) to search for specific policies.

If you have questions or need additional information, reach out via [email](#).

# Policy Updates — Prior Authorization

Simply Healthcare Plans, Inc. | Medicaid and Florida Healthy Kids  
Clear Health Alliance | Medicaid

## Prior authorization update for select durable medical equipment items

Effective June 1, 2022, the following durable medical equipment (DME) codes will require prior authorization (PA).

- E0316 • L2037 • L5301 • L5702 • L5980
- E0986 • L2628 • L5312 • L5814 • L5981
- K0007 • L5050 • L5321 • L5828 • L5988
- K0009 • L5100 • L5590 • L5840 • L5999
- L0999 • L5200 • L5613 • L5845 • L6100
- L1499 • L5210 • L5649 • L5960
- L2034 • L5220 • L5700 • L5968
- L2036 • L5280 • L5701 • L5979

### What is the impact of this change?


Providers should review the list of codes that will require PA. For code-specific PA requirements, visit the [Simply Healthcare Plans, Inc provider website](#) or the [Clear Health Alliance provider website](#).

### How do I obtain precertification?

PA requests can be submitted through the [Availity\\* Portal](#) or by calling Provider Services at **844-405-4296**.

\* Availity, LLC is an independent company providing administrative support services on behalf of Simply Healthcare Plans, Inc. and Clear Health Alliance.

SFL-NL-0421-22



## Simply Healthcare Plans, Inc. expands specialty pharmacy precertification list

Effective for dates of service on and after September 1, 2022, the specialty Medicare Part B drugs listed in the table below will be included in our precertification review process.

Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions and exclusions, take precedence over these precertification rules and must be considered first when determining coverage. Noncompliance with new requirements may result in denied claims.

HCPSC or CPT® codes	Medicare Part B drugs
C9399, J3490, J3590, J9999	Kimmtrak (tebentafusp-tebn)
C9399, J3490, J3590, J9999	Enjaymo (sutimlimab-jome)
C9399, J3590	Tezspire (tezepelumab-ekko)
J3490, J3590	Vabysmo (faricimab-svoa)

SFLCARE-0550-22

[Notice of material amendment to healthcare contract](#)

## Prior authorization updates for medications billed under the medical benefit

Effective for dates of service on and after June 1, 2022, the following medication codes billed on medical claims from current or new *Clinical Criteria* documents will require prior authorization.

Please note, inclusion of a national drug code on your medical claim is necessary to expedite claim processing of drugs billed with a not otherwise classified (NOC) code.

Visit the [Clinical Criteria website](#) to search for the specific *Clinical Criteria* listed below.

<i>Clinical Criteria</i>	HCPSC or CPT® code(s)	Drug name
<b>ING-CC-0096</b>	J9021	Rylaze

Note: Prior authorization requests for certain medications may require additional documentation to determine medical necessity.

SFLPEC-3286-22



# Policy Updates — *Medical Policies and Clinical Guidelines*

The *Medical Policies*, *Clinical Utilization Management (UM) Guidelines*, and *Third-Party Criteria* below were developed and/or revised to support clinical coding edits. Note, several policies and guidelines were revised to provide clarification only and are not included. Existing precertification requirements have not changed.

To view a guideline, visit <https://provider.simplyhealthcareplans.com/florida-provider/medical-policies-and-clinical-guidelines> (Simply Healthcare Plans, Inc.) or <https://provider.clearhealthalliance.com/florida-provider/medical-policies-and-clinical-guidelines> (Clear Health Alliance).

Simply Healthcare Plans, Inc. | Medicaid  
Clear Health Alliance | Medicaid

## August 2021 update

### Notes/updates:

Updates marked with an asterisk (\*) denote that the criteria may be perceived as more restrictive.

- \*CG-SURG-112 — Carpal Tunnel Decompression Surgery
  - Outlines the Medically Necessary and Not Medically Necessary criteria for carpal tunnel decompression surgery
- \*CG-SURG-113 — Tonsillectomy with or without Adenoidectomy for Adults
  - Outlines the Medically Necessary and Not Medically Necessary criteria
- \*LAB.00042 — Molecular Signature Test for Predicting Response to Tumor Necrosis Factor Inhibitor Therapy
  - Molecular signature testing to predict response to Tumor Necrosis Factor inhibitor (TNFi) therapy is considered Investigational & Not Medically Necessary for all uses, including but not limited to guiding treatment for rheumatoid arthritis
- \*OR-PR.00007 — Microprocessor Controlled Knee-Ankle-Foot Orthosis
  - Outlines the Medically Necessary and Not Medically Necessary criteria for the use of a microprocessor controlled knee-ankle-foot orthosis

### Medical Policies

On August 12, 2021, the Medical Policy and Technology Assessment Committee (MPTAC) approved several *Medical Policies* applicable to Simply Healthcare Plans, Inc. (Simply) and Clear Health Alliance (CHA). These guidelines take effect June 3, 2022.

### Clinical UM Guidelines

On August 12, 2021, the MPTAC approved several *Clinical UM Guidelines* applicable to Simply and CHA. These guidelines were adopted by the Medical Operations Committee for our members on September 23, 2021. These guidelines take effect June 3, 2022.



**Read more online.**

SFL-NL-0377-21



## February 2022 update

### Notes/updates:

Updates marked with an asterisk (\*) denote that the criteria may be perceived as more restrictive:

- \*CG-LAB-20 — Thyroid Testing:
  - Outlines the Medically Necessary and Not Medically Necessary criteria for thyroid testing.
- \*CG-LAB-21 — Serum Iron Testing:
  - Outlines the Medically Necessary and Not Medically Necessary criteria for serum iron testing.
- \*LAB.00043 — Immune Biomarker Tests for Cancer:
  - Oncologic immune biomarker tests are considered Investigational and Not Medically Necessary for all indications.
- \*LAB.00044 — Saliva-Based Testing to Determine Drug-Metabolizer Status:
  - Saliva-based testing to determine drug-metabolizer status is considered Investigational and Not Medically Necessary for all indications.
- \*LAB.00045 — Selected Tests for the Evaluation and Management of Infertility:
  - The following tests or procedures are considered Investigational and Not Medically Necessary for diagnosing or managing infertility:
    - Endometrial receptivity analysis
    - Sperm-capacitation test
    - Sperm deoxyribonucleic acid (DNA) fragmentation test
    - Sperm penetration assay
    - Uterine natural killer (uNK) cells test
- \*LAB.00046 — Testing for Biochemical Markers for Alzheimer's Disease:
  - Measurements of biochemical markers (including but not limited to tau protein, AB-42, neural thread protein) is considered Investigational and Not Medically Necessary as a diagnostic technique for individuals with symptoms suggestive of Alzheimer's disease.
  - Measurements of biochemical markers as a screening technique in asymptomatic individuals with or without a family history of Alzheimer's disease is considered Investigational and Not Medically Necessary.
  - Moved content related to biomarker testing for Alzheimer's disease from GENE.00003 Biochemical Markers for the Diagnosis and Screening of Alzheimer's Disease to this document.

- \*RAD.00067 — Quantitative Ultrasound for Tissue Characterization:
  - Quantitative ultrasound for tissue characterization is considered Investigational and Not Medically Necessary for all indications.
- \*SURG.00154 — Microsurgical Procedures for the Prevention or Treatment of Lymphedema:
  - Revised Position Statement to include the prevention of lymphedema.
- \*SURG.00160 — Implanted Port Delivery Systems to Treat Ocular Disease:
  - The use of a port delivery system to treat ocular disease is considered Investigational and Not Medically Necessary for all indications.
- \*TRANS.00038 — Thymus Tissue Transplantation:
  - Outlines the Medically Necessary and Investigational and Not Medically Necessary criteria for allogeneic processed thymus tissue.

### Medical Policies

On February 17, 2022, the Medical Policy and Technology Assessment Committee (MPTAC) approved several *Medical Policies* applicable to Simply Healthcare Plans, Inc. (Simply). These guidelines take effect June 4, 2022.

### Clinical UM Guidelines

On February 17, 2022, the MPTAC approved several *Clinical UM Guidelines* applicable to Simply. These guidelines adopted by the Medical Operations Committee for our members on March 24, 2022. These guidelines take effect June 4, 2022.



**Read more online.**

SHPCRNL-0149-22

# Products and Programs

Simply Healthcare Plans, Inc. | Medicaid and Florida Healthy Kids  
Clear Health Alliance | Medicaid

## Healthy Rewards™ Healthy Behaviors Program information

In accordance with the *Florida Statute 409.973(3)*, as of October 1, 2014, all Medicaid Managed Care (MMC) plans must establish and maintain programs to encourage healthy behaviors. At a minimum, the MMCs are expected to implement medically approved programs for smoking cessation, weight loss, and alcohol or substance use recovery. Simply Healthcare Plans, Inc. and Clear Health Alliance have developed three additional programs for asthma, maternity, and well-child visits.

The program goals and provider roles are shown in the full article.



**Read more online.**

Additional details about each individual program in its entirety are available at <https://simplyhealthcareplans.com>.

SFL-NL-0423-22

